Jazz Pharmaceuticals (JAZZ) PT Raised to $280 at Baird

August 4, 2026 6:13 AM

Baird analyst Brian Skorney raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $280.00 (from $252.00) while maintaining a Outperform rating.

No results found